Efficacy and Safety of Semaglutide 2.4 mg by Race and Ethnicity
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Key messages
- This study assessed response and tolerability to semaglutide treatment among participants in the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials (US- or global-based, randomized, placebo-controlled, phase 3 trials evaluating the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg) by self-identified racial and ethnic subgroups.
- The primary outcome was the estimated treatment difference (ETD) for semaglutide vs placebo in percent weight change, and adverse events were analyzed descriptively.
- In the pooled sample, the ETD (95% CI) for Asian, Black, White, and other participants were −9.7 (−12.1 to −7.3), −11.6 (−14.3 to −8.9), −12.5 (−13.4 to −11.6), and −9.3 (−12.8 to −5.7) percentage points, respectively.
- The ETD (95% CI) for not Hispanic or Latino, Hispanic or Latino, and patients with unknown ethnicity were −12.1 (−13.0 to −11.2), −10.9 (−13.1 to −8.8), and −9.6 (−14.8 to −4.3) percentage points, respectively.
- There was no significant evidence of interaction between the treatment effect and race (P=0.0758) or ethnicity (P=0.4042), and the safety of semaglutide was generally consistent across subgroups.
Presenting Author
About this Medfyle
This is a summary of an oral session given at the ObesityWeek® 2022 and presented by:
Mahmoud M. Abulmeaty, MD, PhD, FACN
King Saud University Medical City
Riyadh, Saudi Arabia
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference summary.
About the Expert
Ken Fujioka, MD
Scripps Clinic
San Diego, CA, USA
Dr. Ken Fujioka is the director of the Nutrition and Metabolic Research Center at Scripps Clinic in San Diego, California.
He has special clinical interests in the medical management of diabetes in overweight people, and in helping those who are seriously overweight lose weight.
Dr. Fujioka is a frequent lecturer at national conferences, speaking on the role of weight control and diabetes. Dr. Fujioka has published numerous research papers and has completed many clinical trials in the field of obesity and related diseases including diabetes, hypercholesterolemia and hypertension.
